

U.S. Patent No. 5,932,211. Enclosed herewith is a terminal disclaimer in compliance with 37 C.F.R. §1.321(c). Also enclosed is a check in the amount of \$110.00 pursuant to 37 C.F.R. §1.20(d). Withdrawal of the rejection of claims 1-6, 11-12 and 16-26 under the judicially created doctrine of double patenting is therefore warranted.


Claims 1-6, 11-12, and 16-26 have been rejected under 35 U.S.C. §112, first paragraph, as drawn to subject matter which is allegedly not enabled by the specification. In the interest of expediting prosecution of this application, and without acquiescing to the position taken by the Examiner, claims 1, 3, 11, 16, 17, 18, 19, 20, 21, and 22 have been amended to delete recitations to fragments of IDS retaining enzymatic activity. Applicants reserve the right to file one or more continuation applications directed to enzymatically active fragments of IDS and pharmaceutical fragments comprising same. Withdrawal of the rejection of claims 1-6, 11-12, and 16-26 is respectfully requested.

Claims 5-6 have been rejected under 35 U.S.C. §112, second paragraph, as allegedly indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, claims 5 and 6 recite a recombinant IDS while referring to SEQ ID NO:1 which is a nucleotide sequence. In order to obviate the rejection, Applicants have amended claims 5 and 6 to recite SEQ ID NO:2, which is the corresponding amino acid sequence. Withdrawal of the rejection of claims 5-6 under 35 U.S.C. §112, second paragraph is respectfully requested.

C

In view of the foregoing remarks and amendments, it is firmly believed that the present application is in condition for allowance, with action is earnestly solicited.

Respectfully submitted,



Ann R. Pokalsky  
Reg. No. 34,697

SCULLY SCOTT MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343  
ARP:vjs

